Novo Nordisk expands digital health partnerships to enhance GLP-1RA weight loss outcomes

Key Takeaways:

• Novo Nordisk launches the Novo Nordisk Partner Platform to integrate digital tools into the care pathway for individuals using semaglutide (Wegovy) for weight loss.
• The initiative seeks collaborations with AI-powered nutrition apps, body composition scanners, telehealth services, and pharmacies to improve clinical outcomes.
• The company aims to consolidate its leadership in the global weight loss market amidst growing competition from Eli Lilly and expanding its obesity pipeline beyond GLP-1 receptor agonists.
  

Strategic Expansion Through Digital Integration

Novo Nordisk has unveiled a new initiative designed to enhance the weight loss outcomes of people receiving treatment with its glucagon-like peptide-1 receptor agonist (GLP-1RA), semaglutide, marketed as Wegovy for obesity and Ozempic for type 2 diabetes. The company is now seeking partnerships with digital health innovators across all stages of the weight management journey to better support individuals in achieving and maintaining clinically significant weight loss.

This effort is being formalised through the Novo Nordisk Partner Platform (NNPP), announced at the HLTH Europe conference in Amsterdam, held from 16 to 19 June. The announcement was made by Anne Cathrine Fleischer, Vice President of Global Obesity Consumer Engagement and New Business Models at Novo Nordisk.

A Digital Ecosystem for Personalised Support

Fleischer described the NNPP as a strategy to build a “marketplace of selected solutions” designed to complement pharmacological treatment with digital support. “The idea is that we create this ecosystem or marketplace of selected solutions that people can pick and choose from, so when a patient has started treatment, we know they have received help,” she said.

She continued: “We know when we look at our own digital tools that when intervention is combined with those efficient weight loss medications, patients are receiving better weight loss, so we hope we can significantly improve outcomes by combining education with digital tools.”

Through this platform, individuals prescribed semaglutide for weight management will gain access to additional services such as exercise coaching and nutritional guidance, either via the Novo Nordisk website or its Novo Care platform. The company is also exploring the development of a consolidated mobile application to house these resources in one accessible interface.

Targeting Muscle Loss and Optimising Nutrition

A particular focus for the company is addressing muscle mass loss, a known issue associated with GLP-1RA therapies. Novo Nordisk is in discussions with a technology partner whose AI-powered application can scan a person’s plate of food and assess whether it meets their nutritional requirements – especially protein intake.

In addition, the company is exploring collaborations with developers of mobile apps that scan body composition, allowing individuals to monitor changes in lean mass and fat distribution throughout their treatment.

Broader Partnerships to Enhance the Care Pathway

In a bid to offer more integrated care, Novo Nordisk is also seeking partnerships with telehealth providers and community pharmacies to deliver accessible medical advice to people receiving GLP-1RA treatment. “By partnering with these players, we can provide a much better patient journey and care pathway,” Fleischer added.

The company’s approach reflects a broader ambition to deliver not just medication, but a holistic model of obesity care that supports long-term behavioural change and health outcomes.

Advancing the Competitive Edge in Obesity Care

Novo Nordisk’s push into digital health partnerships comes as it faces growing competition from Eli Lilly. Earlier this year, Lilly’s dual agonist Zepbound (tirzepatide) demonstrated superior weight loss outcomes to Wegovy in a Phase III clinical trial. Novo Nordisk is responding by accelerating the development of its next-generation therapies.

In early June, the company announced that it had moved both subcutaneous and oral formulations of amycretin into Phase III trials for people living with obesity or overweight. It has also launched two additional Phase III trials of CagriSema, another pipeline candidate.

Further, Novo Nordisk has strengthened its drug discovery capabilities through an $812 million partnership with Deep Apple Therapeutics, aimed at identifying novel small molecules for obesity and other conditions that target pathways beyond GLP-1. This was complemented by a strategic collaboration with NVIDIA, leveraging advanced AI technologies to support future drug development.

With the launch of the NNPP, Novo Nordisk aims to not only optimise outcomes for individuals prescribed GLP-1RAs but also to solidify its leadership in the increasingly competitive obesity treatment landscape by embedding digital innovation across the full spectrum of care.